OMER Omeros Corporation Gross Profitability Margin

Official company branding of Omeros (OMER)

Omeros Corporation risks facing patent pressure from industry behemoths, yet it minimizes dependencies through long-term contracts with research networks. Gross margin dynamics on the GURU.Markets service clearly resolve this dispute, where the value of 95.90 captures the metric level. Business stability is supported by laboratories in Washington, which delegate drug production to external certified plants.

Gross Profitability: Omeros Corp. (OMER) for 07/04/2022 - 11/19/2026

Comprehensive metric breakdowns and analytics for omeros.com (OMER)

- stock price and consensus target price:
Fundamental valuation:OMER - omeros.com
Manufactured product of Omeros Corporation

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for the identification of hidden yield compression prior to the publication of financial statements. The current value of 95.90 and the gross margin trend reflect the efficiency of supply chain optimization for active ingredients at Omeros Corporation, where laboratory diversification minimizes logistics costs and ensures capital stability.

Main competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Gross Profit Margin Neurogene Inc. (NGNE)|Return on Gross Profit ACIU|Gross Profitability VYGR|Gross Profitability Neumora (NMRA)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)